Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study.
Poissonnet V, Chabrillac E, Uro-Coste E, Woisard V, Moya-Plana A, Espitalier F, Castelli J, Dedieu T, Salas S, Garrel R, Baudouin R, Poissonnet G, Castain C, Barbut J, Mirghani H, Evrard D, Bouchain O, Marie JP, Orliac H, Ceruse P, Dufour X, Brenet E, Rambeau A, Herman P, Abu Shama Y, Bertolus C, Atallah S, Morinière S, Righini C, Mouawad F, Duflo S, Segier B, Vergez S. Poissonnet V, et al. Among authors: salas s. Oral Oncol. 2024 Oct 20;159:107072. doi: 10.1016/j.oraloncology.2024.107072. Online ahead of print. Oral Oncol. 2024. PMID: 39432991 Free article.
Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis.
Chatelet F, Chevret S, Fakhry N, Even C, Malard O, de Monès E, Saroul N, Mouawad F, de Boutray M, Mauvais O, Vergez S, Evrard D, Righini C, Schultz P, Baudouin R, Poissonnet G, Atallah S, Haroun F, Morinière S, Evrard C, Philouze P, Paasche A, Lesnik M, Lelonge Y, Herman P, Verillaud B; REFCOR members. Chatelet F, et al. Eur J Surg Oncol. 2024 Oct 10:108746. doi: 10.1016/j.ejso.2024.108746. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39424524 Free article.
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F, Chaigneau L, Collard O, Pracht M, Henon C, Ray-Coquard I, Armoun K, Salas S, Spalato-Ceruso M, Adenis A, Verret B, Penel N, Moreau-Bachelard C, Italiano A, Dufresne A, Metzger S, Chabaud S, Perol D, Le Cesne A. Blay JY, et al. Among authors: salas s. Ann Oncol. 2024 Sep 4:S0923-7534(24)03924-3. doi: 10.1016/j.annonc.2024.08.2343. Online ahead of print. Ann Oncol. 2024. PMID: 39241959 Free article.
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Blay JY, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, Bompas E, Verret B, Ray-Coquard I, Salas S, Henon C, Honoré C, Brahmi M, Dufresne A, Pracht M, Hervieu A, Penel N, Bertucci F, Rios M, Saada-Bouzid E, Soibinet P, Perol D, Chabaud S, Italiano A, Cesne AL. Blay JY, et al. Among authors: salas s. Lancet Oncol. 2024 Sep;25(9):1163-1175. doi: 10.1016/S1470-2045(24)00318-8. Epub 2024 Aug 7. Lancet Oncol. 2024. PMID: 39127063 Clinical Trial.
367 results